The aim of the current study was to explore the impact of implementing the Elecsys AMH Plus immunoassay to identify PCOM as part of PCOS assessment in women with signs and symptoms, from the perspective of the UK NHS. This evidence concerns the gene AMH and polycystic ovary syndrome.